Skip to main content

Roland Walter, MD PhD

Seattle, WA
United States

Fred Hutchinson Cancer Center

Dr. Walter’s research focuses on AML. He is particularly interested in improving antibody-based therapies by optimizing existing therapeutics and through the development of novel antigen-directed therapies. As examples of the latter, his lab has helped with candidate drug identification and characterization of 5 agents that have subsequently advanced to clinical testing. A major area of focus of his research lies in the delineation of the mechanisms of action and resistance that are relevant for antibody-based AML therapeutics and the rational development of combination therapies that can overcome drug resistance. Many of his studies conducted over the last 20 years have aimed at optimizing CD33- and, more recently, CD123-targeted therapies. In clinical studies, Dr. Walter conducts trials testing novel treatments and innovative care approaches for AML patients. Furthermore, he uses large datasets to develop and improve diagnostic and prognostic tools for people with AML.

Program Name(s)
Translational Research Program
Dr. Walter